Publications by authors named "Michael B Atkins"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

96

Total Likes

215

Extended Reach

1,286,983

Social Features

183
M
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marc S Ernstoff, Jennifer M Gardner, Pamela Ginex

June 2018

Videos about Article: user user

2 2 6 179 4 82

View All Article and Social Media Activity
D
Differentiated Thyroid Cancer Is Associated With Sex-specific Immune Response.
Leila Shobab, Jennifer Simpson, Matthew McCoy, Hui Zheng, Sonam Kumari, Michael B Atkins

J Endocr Soc· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
Rana R McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges, Michael B Atkins

CA Cancer J Clin· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations Between Anxiety or Depression Diagnosis and Immune Checkpoint Inhibitor Outcomes.
Heather Derry-Vick, Neil J Shah, Jaeil Ahn, Bianca DeAgresta, Alexandra Della Pia, Michael B Atkins

Cancer Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.
Meredith M Regan, Paolo A Ascierto, Evan J Lipson, Jennell Palaia, Andriy Moshyk, Michael B Atkins

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilizing Immuno-Oncology registry data for enhanced non-small cell lung cancer treatment predictions.
Yili Zhang, Shaked Lev-Ari, Jacob Zaemes, Alexandra Della Pia, Bianca DeAgresta, Michael B Atkins

JAMIA Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How can we increase the value of clinical trials with immunotherapy?
Michael B Atkins, David F Mcdermott

J Immunother Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary: Appropriate Use Criteria for F-FDG PET/CT for Initial Staging of Malignant Disease.
Hossein Jadvar, Michael B Atkins, Twyla Bartel, Lioe-Fee de Geus-Oei, Elizabeth H Dibble

J Nucl Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.
Charlene M Mantia, Opeyemi A Jegede, David F McDermott, Daniel Y C Heng, Wanling Xie, Michael B Atkins

JCO Oncol Pract· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology.
Sumit Mukherjee, Sumeet Patiyal, Lipika R Pal, Tian-Gen Chang, Sumona Biswas, Michael B Atkins

bioRxiv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.
Miya B Hugaboom, Lena V Wirth, Kelly Street, Neil Ruthen, Opeyemi A Jegede, Michael B Atkins

Cancer Discov· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.
Elizabeth Buchbinder, Michael T Lotze, Kim A Margolin, Rodabe Amaria, Amod Sarnaik, Michael B Atkins

J Immunother Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials.
Sarah N Price, Ju-Whei Lee, Ilana F Gareen, Sheetal M Kircher, Shaji K Kumar, Michael B Atkins

J Pain Symptom Manage· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
Raymond Y Huang, Gilbert Youssef, Thomas Nelson, Patrick Y Wen, Peter Forsyth, Michael B Atkins

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
Georgina V Long, James Larkin, Dirk Schadendorf, Jean-Jacques Grob, Christopher D Lao, Victoria Atkinson, Michael B Atkins

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How should we approach salvage therapy in advanced renal cell carcinoma after first-line immunotherapy combinations?
Paul Sackstein, Michael B Atkins

Expert Opin Biol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a Tailored Mobile Messaging Intervention for Indoor Tanning Cessation in Young Females: A Randomized Clinical Trial.
Darren Mays, Mahmood A Alalwan, Lauren Long, Michael B Atkins, Kenneth P Tercyak

Cancer Epidemiol Biomarkers Prev· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study.
Miguel Zugman, David F McDermott, Bernard J Escudier, Thomas E Hutson, Camillo Porta, Michael B Atkins

Oncologist· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late radiation-related lymphopenia after prostate stereotactic body radiation therapy plus or minus supplemental pelvic irradiation.
Kelly Gaudian, Min Jung Koh, Min Ji Koh, Peter Jermain, Irfan Khan, Michael B Atkins

Front Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma.
Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura Fernandes, Michael B Atkins

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer, Michael B Atkins

J Immunother Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials.
Neil J Shah, Alexandra Della Pia, Tianmin Wu, Aquino Williams, Melinda Weber, Michael B Atkins

Cancers (Basel)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen

J Immunother Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Kathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, Bernard Escudier, Thomas E Hutson

Oncologist· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients.
Thomas Denize, Opeyemi A Jegede, Sayed Matar, Nourhan El Ahmar, Destiny J West, Michael B Atkins

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
Elizabeth R Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Michael B Atkins

Eur Urol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis